RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news'

Go back to RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news'

Baird on Mirum Pharmaceuticals (MIRM): 'we expect upside for the stock'

October 12, 2026 9:34 AM EDT

Baird analyst Brian Skorney reiterated an Outperform rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst comments "Incrementally positive on EXPAND success. Mirum announced the Ph3 EXPAND basket study of maralixibat in additional cholestatic indications, about half biliary atresia patients,... More